アンギオテンシン変換酵素阻害薬の血行動態  [in Japanese] Hemodynamics of Angiotensin Converting Enzyme Inhibitors  [in Japanese]

Access this Article

Author(s)

Abstract

アンギオテンシン変換酵素阻害薬は,まだ不明な点も多くさらなる研究を必要とするが,その効果については多くの臨床例で認められている。心不全の治療薬としては,その安全性の高さや治療効果から第一選択薬としての地位を獲得していると考えられる。

Several large, prospective, randomized, placebo-controlled trials have demonstrated that treatment with Angiotensin Converting Enzyme (ACE) inhibitors results in a reduction in overall mortality in human and small animal, patients with heart failure. ACE regulates the balance between the vasoconstrictive, salt-retensive, and hypertrophic properties of angiotensin II and the vasodilatory and naturetic properties of bradykinin. ACE inhibitors alter this balance by decreasing the formation of angiotensin II and the degradation of bradykinin. ACE inhibitors also indirectly alter the metabolism of a number of other vasoactive substances and diuretic hormon; NO, prostagrandin, and endothelin, and ADH, etc. ACE inhibitors decrease systemic vascular resistance but cause little change in heart rate. ACE inhibitors have effect on cardiac output or pulmonary capillary wedge pressure. It is clear that ACE inhibitors represent one of major advances in cardiovascular therapeutics in small animal cardiovascular medicine.

Journal

  • Advances in Animal Cardiology

    Advances in Animal Cardiology 31(2), 53-58, 1998-12-01

    Japanese Society of Veterinary Cardiology

References:  20

Codes

  • NII Article ID (NAID)
    10008287451
  • NII NACSIS-CAT ID (NCID)
    AN10192925
  • Text Lang
    JPN
  • Article Type
    REV
  • ISSN
    09106537
  • NDL Article ID
    4805987
  • NDL Source Classification
    ZR22(科学技術--農林水産--畜産)
  • NDL Call No.
    Z18-1508
  • Data Source
    CJP  NDL  J-STAGE  JASI 
Page Top